Please wait a minute...
Reviews in Cardiovascular Medicine  2016, Vol. 17 Issue (S1): 22-29     DOI: 10.3909/ricm17S1S0003
Heat Failure University Previous articles | Next articles
A Treatment Approach for Patients With Chronic Systolic Heart Failure
Barry H. Greenberg
Department of Medicine, Cardiology Division, University of California-San Diego, La Jolla, CA
Download:  PDF(769KB)  ( 89 )
Export:  BibTeX | EndNote (RIS)      
Abstract:
The treatment of heart failure with reduced ejection (HFrEF) is changing rapidly. Advances over the past several decades have focused on blocking the adverse effects of neurohormonal activation. This approach has resulted in marked improvement in outcomes in the HFrEF population. Despite these advances, however, mortality and morbidity remain high and HFrEF patients have poor quality of life. New approaches to therapy now offer additional benefits. Combined neprilysin inhibition and angiotensin receptor blockade using sacubitril-valsartan (LCZ696) has been shown to be superior to an angiotensin-converting enzyme inhibitor in HFrEF patients. Compared with enalapril, treatment with LCZ696 was associated with significant reductions in the composite of cardiovascular mortality and heart failure hospitalization, both components of this composite endpoint and all-cause mortality. Another approach that has been shown to be effective is the use of ivabradine, an agent that blocks I f channels in the sinus node to reduce heart rate. When added to standard therapy (that included a β-blocker in 89% of patients) in symptomatic HFrEF patients who were in sinus rhythm, ivabradine significantly reduced combined cardiovascular mortality and heart failure hospitalizations. Death from heart failure, all-cause hospitalization, and heart failure hospitalization were also significantly reduced when ivabradine was added to the medical regimen. Thus, both LCZ696 and ivabradine represent significant advances in the therapy of HFrEF. Utilization of these drugs in the growing HFrEF population will benefit millions of patients around the world.
Key words:  Heart failure      Neurohormones      LCZ696      Ivabradine     
Published:  20 January 2016     

Cite this article: 

Barry H. Greenberg. A Treatment Approach for Patients With Chronic Systolic Heart Failure. Reviews in Cardiovascular Medicine, 2016, 17(S1): 22-29.

URL: 

https://rcm.imrpress.com/EN/10.3909/ricm17S1S0003     OR     https://rcm.imrpress.com/EN/Y2016/V17/IS1/22

[1] Chiara Minà, Laura Ajello, Gabriele Di Gesaro, Calogero Falletta, Francesco Clemenza. Hyperkalemia in heart failure: current treatment and new therapeutic perspectives[J]. Reviews in Cardiovascular Medicine, 2020, 21(2): 241-252.
[2] Amir Kazory, Maria Rosa Costanzo. The dynamic relationship between serum chloride and cardiorenal syndrome[J]. Reviews in Cardiovascular Medicine, 2020, 21(1): 25-29.
[3] Megan S. Joseph, Maryse Palardy, Nicole M. Bhave. Management of heart failure in patients with end-stage kidney disease on maintenance dialysis: a practical guide[J]. Reviews in Cardiovascular Medicine, 2020, 21(1): 31-39.
[4] Xiaogen Chen, Chunna Jin, Lan Xie, Meixiang Xiang. LCZ696 and preservation of renal function in heart failure: A meta-analysis of 6 randomized trials[J]. Reviews in Cardiovascular Medicine, 2020, 21(1): 113-118.
[5] Akanksha Agrawal, Hafeez Ul Hassan Virk, Iqra Riaz, Deepanshu Jain, Byomesh Tripathi, Chayakrit Krittanawong, Benham Bozorgnia, Vincent Figueredo, Peter A. McCullough, Janani Rangaswami. Predictors of 30-day re-admissions in patients with infective endocarditis: a national population based cohort study[J]. Reviews in Cardiovascular Medicine, 2020, 21(1): 123-127.
[6] Hesam Mostafavi Toroghi, Kevin Bryan Lo, Mary Rodriguez Ziccardi, Benjamin Horn, Napatt Kanjanahattakij, Erum Malik, Jorge Penalver, Janani Rangaswami, Shuchita Gupta, Aman Amanullah. Renal implications of pulmonary arterial capacitance in acute heart failure with preserved ejection fraction[J]. Reviews in Cardiovascular Medicine, 2019, 20(4): 267-272.
[7] Girish Singhania, Abutaleb A. Ejaz, Peter A. McCullough, Aaron Y. Kluger, Saravanan Balamuthusamy, Bhagwan Dass, Namrata Singhania, Adhish Agarwal. Continuation of Chronic Heart Failure Therapies During Heart Failure Hospitalization - a Review[J]. Reviews in Cardiovascular Medicine, 2019, 20(3): 111-120.
[8] Victoria E. Tril, Alla V. Burlutskaya, Lily V. Polischuk. Metabolic cardiomyopathy in pediatrics[J]. Reviews in Cardiovascular Medicine, 2019, 20(2): 73-80.
[9] Janani Rangaswami, Sandeep Soman, Peter A. McCullough. Key updates in Cardio-Nephrology from 2018: springboard to a bright Future[J]. Reviews in Cardiovascular Medicine, 2018, 19(4): 113-116.
[10] John E. Dudzinsk, Eric Gnall, Peter R. Kowey. A Review of percutaneous mechanical support devices and strategies[J]. Reviews in Cardiovascular Medicine, 2018, 19(1): 21-26.
[11] Nasrien E. Ibrahim, Akshay S. Desai, Jagmeet P. Singh, James L. Januzzi Jr. Advances in Heart Failure Management: Improving Outcomes With Innovation[J]. Reviews in Cardiovascular Medicine, 2017, 18(S1): 1-16.
[12] Saberio Lo Presti, Christos G. Mihos, Evin Yucel, Sofia A. Horvath, Orlando Santana. A Focused Review on the Pathophysiology, Diagnosis, and Management of Cardiac Amyloidosis[J]. Reviews in Cardiovascular Medicine, 2017, 18(4): 123-133.
[13] Claudio Ronco, Federico Ronco, Peter A. McCullough. A Call to Action to Develop Integrated Curricula in Cardiorenal Medicine[J]. Reviews in Cardiovascular Medicine, 2017, 18(3): 93-99.
[14] Jürgen Kuschyk, Axel Kloppe, Stephan Schmidt-Schweda, Hendrik Bonnemeier, Benny Rousso, Susanne Rger. Cardiac Contractility Modulation: A Technical Guide for Device Implantation[J]. Reviews in Cardiovascular Medicine, 2017, 18(1): 1-13.
[15] Nasrien E. Ibrahim, Akshay S. Desai, Jagmeet P. Singh, James L. Januzzi Jr. Heart Failure University 2015: Presentation Summaries[J]. Reviews in Cardiovascular Medicine, 2016, 17(S1): 1-8.
No Suggested Reading articles found!